Q2 2012 · 10-Q
Revenue$14.60M$14.60M +29.7% vs Q2 2011+19.2% vs Q1 2012
Net income—
EPS Diluted-$0.38-$0.38 N/M vs Q2 2011N/M vs Q1 2012
Operating Income-$40,834,000N/M
Operating Cash Flowderived-$43,107,000N/M
Free Cash Flowderived-$45,502,000N/M
Margins · derived
Operating margin-279.6%−111.3 pt vs Q2 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|
| Revenue | $14.60M | $11.26M | $9.19M |
| Net Income | — | -$18.84M | -$17.14M |
| EPS Diluted | -$0.38 | -$0.19 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR